Also trades as: 0HKF.L (LSE) · $vol 0M
AXSM NASDAQ
Axsome Therapeutics, Inc.
1W: -8.1%
1M: -14.6%
3M: -26.1%
YTD: +0.3%
1Y: +51.2%
3Y: +148.0%
5Y: +436.7%
$179.25
-2.82 (-1.55%)
Weekly Expected Move ±5.7%
$159
$169
$179
$189
$200
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Find alpha in the revenue growth fog - Goldman
Bank of America Corp DE Acquires Shares of 452,491 Axsome Therapeutics, Inc. $AXSM
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Is Axsome Therapeutics a Buy on the Dip?
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Baird Financial Group Inc. Acquires New Holdings in Axsome Therapeutics, Inc. $AXSM
Goldman rebalances its long duration stock basket
Axsome rises on Auvelity prescription data
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
Hsbc Holdings PLC Sells 12,653 Shares of Axsome Therapeutics, Inc. $AXSM
Monthly top ideas from Oppenheimer include MA, MRVL, CMG, and more
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Bamco Inc. NY Makes New Investment in Axsome Therapeutics, Inc. $AXSM
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
BlackRock Inc. Invests $759.70 Million in Axsome Therapeutics, Inc. $AXSM
Dimensional Fund Advisors LP Purchases 2,729 Shares of Axsome Therapeutics, Inc. $AXSM
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say
Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates
Here are the major earnings before the open Monday
Assenagon Asset Management S.A. Cuts Stock Holdings in Axsome Therapeutics, Inc. $AXSM
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates
Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates
Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks
New Strong Sell Stocks for July 31st
New Strong Sell Stocks for July 29th
New Strong Sell Stocks for July 27th
Caxton Associates LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
3 Under-the-Radar Stocks to Buy and Hold
Better Growth Buy: Axsome vs Revolution Medicines
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
Why Is Axsome (AXSM) Down 0.4% Since Last Earnings Report?
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
3 Stocks Poised to Disrupt the Healthcare Market by 2030
Axsome Therapeutics Recognizes Mental Health Month
Axsome Therapeutics Recognizes Mental Health Month
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
3 Overlooked Stocks Set to Soar in 2026
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
Axsome (AXSM) Q1 2026 Earnings Call Transcript
Axsome (AXSM) Q2 2025 Earnings Transcript
Axsome (AXSM) Q1 2025 Earnings Call Transcript
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
Here's What Key Metrics Tell Us About Axsome (AXSM) Q1 Earnings
Axsome Therapeutics Q1 2026 Earnings Call: Complete Transcript
Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
Earnings Scheduled For May 4, 2026
Axsome Therapeutics GAAP EPS of -$1.26 misses by $0.36, revenue of $191.2M beats by $0.51M
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
William Blair updates conviction stock list
Here are the major earnings before the open Monday
Why Axsome Therapeutics Stock Jumped Over 20% in April
Axsome Therapeutics Q1 2026 Earnings Preview
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression
Axsome wins FDA label expansion for Auvelity in Alzheimer’s agitation
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Franklin Street Advisors Inc. NC Makes New Investment in Axsome Therapeutics, Inc. $AXSM
Is This Healthcare Stock a Millionaire Maker?
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
SG Americas Securities LLC Acquires 5,584 Shares of Axsome Therapeutics, Inc. $AXSM
SG Americas Securities LLC Acquires 5,584 Shares of Axsome Therapeutics, Inc. $AXSM
Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?
Axsome Therapeutics, Inc. $AXSM Position Increased by Assenagon Asset Management S.A.